Clinical Research Papers:

Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study

Peng Xing, Huiting Dong, Qun Liu, Fan Yao, Yingying Xu, Bo Chen, Xinyu Zheng, Yunfei Wu, Feng Jin _ and Jiguang Li

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:102499-102510. https://doi.org/10.18632/oncotarget.18454

Metrics: PDF 1209 views  |   HTML 2079 views  |   ?  


Peng Xing1, Huiting Dong1, Qun Liu1, Fan Yao1, Yingying Xu1, Bo Chen1, Xinyu Zheng1, Yunfei Wu1, Feng Jin1 and Jiguang Li1

1Breast Division, The First Hospital of China Medical University, Shenyang 110001, Liaoning, People’s Republic of China

Correspondence to:

Feng Jin, email: [email protected]

Keywords: breast cancer, endocrine therapy, treatment persistence, risk factors

Received: December 07, 2016     Accepted: May 22, 2017     Published: June 12, 2017


The purpose of this prospective study is to investigate the impact of endocrine treatment persistence on the survival of patients with estrogen receptor-positive breast cancer treated with endocrine therapy and identify the risk factors influencing the treatment persistence. We enrolled 1085 patients from Northeast China who were diagnosed as stage I–III, estrogen receptor-positive breast cancer between January 2007 and December 2010. The prognostic factors for disease-free survival (DFS) and overall survival (OS) of patients were identified using univariate and multivariate Cox proportional hazards regression models. Multiple logistic regression analysis was done to determine the possible risk factors for non-endocrine treatment and treatment discontinuation. Among the patients enrolled, 598 (55.1%) underwent 5 years of endocrine therapy, 278 (25.6%) less than 5 years, and 209 (19.3%) non-endocrine therapy. OS rates in the continuation, discontinuation, and non-endocrine treatment groups were 97.8%, 92.6% and 74.3%, and DFS 97.5%, 86.2% and 69.9%, respectively. After adjusting for pathological and socioeconomic factors, non-endocrine therapy and discontinuation were independent predictors for DFS and OS. Elderly patients (≥ 65 years), those living in suburban and rural areas, locally advanced patients, and receiving no radiotherapy and/or chemotherapy were more likely to receive non-endocrine therapy and discontinue endocrine treatment. In conclusion, the prospective study demonstrate that the persistence of endocrine treatment is low in estrogen receptor-positive breast cancer patients in Northeast China. Non-endocrine treatment and early discontinuation serve as independent prognostic factors for both DFS and OS of breast cancer patients treated with endocrine therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18454